Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.
Usman
N
N
Research and Development, Ribozyme Pharmaceuticals Inc., Boulder, Colorado 80301, USA. usmann@rpi.com
Blatt
L M
LM
D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy*; D002384:Catalysis; D004795:Enzyme Stability; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D020871:RNA Stability; D016337:RNA, Catalytic / Q000138:chemical synthesis / Q000627:therapeutic use*; D012260:Ribonucleases / Q000378:metabolism
C121301:Angiozyme; D016337:RNA, Catalytic; D012260:Ribonucleases